CVM is iaesscaodt iwth nceiingtf norga alspatrnnt e.ttpnasi MCV si emtrattsdin vai eulsax tt,ocnca argno anstal,pntr or icyletarlv via p.eltcnaa eitnoavaictR of MCV oscruc in hte emoresnupsp.sdimu
ganrO rattsaplnn ispaentt are ta na esndceair rksi of VCM emoau.npni
eh swa vnere eving rclocnviaig - i dues taht as a cule oevr pnsaarnttl reciontje
Why udwlo this ont be atuec atlaprnnst eejicnrto gdelian ot RADS? hTe reanniitec si leeevat,d dan I ees ayn esnrao why ti dwuol be letdveae edybon nojetecir
via @sammyj98 via UpToDate:
Universal prophylaxis with valganciclovir
or ganciclovir
is typically given to patients at risk for cytomegalovirus (CMV) reactivation (eg, seropositive recipients and those with seropositive donors). The duration of therapy often depends on the type of organ transplanted, the risk status of the patient, and individual institutional practice. Some transplant centers prefer to use a pre-emptive approach (eg, routine CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations.
submitted by โamorah(115)
eeFvr &t;g- relu uot letf nreilcatvru uifelar T S-PMXM lsxypaophri -> rlue out ssnPicemyuot vyecej inrdoiKi pttnalnsra utb on BBCC/RW in reniu gt;&- eurl uto nsnatlaprt onerctjei
Lneavig CVM nda ptclyaia utacemboycmir as hte inignmear owt oponis.t VMC is omre yillke in a pnlasnttra pen.ttia